STRUCTURE-ACTIVITY-RELATIONSHIPS IN THE 8-AMINO-6,7,8,9-TETRAHYDRO-3H-BENZ[E]INDOLE RING-SYSTEM .2. EFFECT OF 8-AMINO NITROGEN SUBSTITUTION ON SEROTONIN RECEPTOR-BINDING AND PHARMACOLOGY

被引:10
作者
ENNIS, MD
STJERNLOF, P
HOFFMAN, RL
GHAZAL, NB
SMITH, MW
SVENSSON, K
WIKSTROM, H
HAADSMASVENSSON, SR
LIN, CH
机构
[1] UPJOHN CO,UPJOHN LABS,CHEM & BIOL SCREENING,KALAMAZOO,MI 49001
[2] UPJOHN CO,UPJOHN LABS,CENT NERVOUS SYST RES,KALAMAZOO,MI 49001
[3] GOTHENBURG UNIV,DEPT PHARMACOL,MED CHEM UNIT,S-41390 GOTHENBURG,SWEDEN
[4] UNIV GRONINGEN,CTR PHARM,DEPT MED CHEM,9713 AW GRONINGEN,NETHERLANDS
关键词
D O I
10.1021/jm00012a022
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of analogs of the potent and selective 5-HT1A agonist 8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1-carbaldehyde (2b) (OSU191) was prepared in which the dipropylamino group was modified to bear a variety of substituents. These compounds were evaluated for both in vitro and in vivo effects, including the establishment of a receptor binding profile for these analogs at the 5-HT1A, dopamine D-2, dopamine D-3, 5-HT1D alpha, and 5-HT1D beta sites. Several of the analogs were evaluated for their biochemical effects in reserpinized rats, specifically with regard to in vivo changes in brain levels of 5-HTP and DOPA. Nearly all of the compounds prepared for this study were exceedingly potent at the 5-HT1A receptor, although most also displayed significant affinity for the dopamine D-2 receptor. A strong preference for the 5-HT1D alpha, over the 5-HT1D beta receptor was also apparent. An analog bearing a butylglutarimide side chain, S-7k, was extremely selective for the 5-HT1A receptor. Although this compound possessed a K-i of 0.6 nM, it elicited only modest changes in 5-HTP brain levels. However, this compound did not appear as an antagonist when tested in a cyclic-AMP-based intrinsic activity assay.
引用
收藏
页码:2217 / 2230
页数:14
相关论文
共 30 条
[1]  
AGHAJANIAN GK, 1972, P S DRUG ABUSE METAB, P115
[2]  
ANDEN NE, 1961, ANNU REV PHARMACOL, V9, P119
[3]   8-HYDROXY-2-(DI-NORMAL-PROPYLAMINO)TETRALIN, A NEW CENTRALLY ACTING 5-HYDROXYTRYPTAMINE RECEPTOR AGONIST [J].
ARVIDSSON, LE ;
HACKSELL, U ;
NILSSON, JLG ;
HJORTH, S ;
CARLSSON, A ;
LINDBERG, P ;
SANCHEZ, D ;
WIKSTROM, H .
JOURNAL OF MEDICINAL CHEMISTRY, 1981, 24 (08) :921-923
[4]   DRUG DESIGN VIA PHARMACOPHORE IDENTIFICATION - DOPAMINERGIC ACTIVITY OF 3H-BENZ[E]INDOL-8-AMINES AND THEIR MODE OF INTERACTION WITH THE DOPAMINE RECEPTOR [J].
ASSELIN, AA ;
HUMBER, LG ;
VOITH, K ;
METCALF, G .
JOURNAL OF MEDICINAL CHEMISTRY, 1986, 29 (05) :648-654
[5]  
BIENKOWSKI M, COMMUNICATION
[6]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[7]   A 2ND MOLECULAR-FORM OF D2 DOPAMINE RECEPTOR IN RAT AND BOVINE CAUDATE-NUCLEUS [J].
CHIO, CL ;
HESS, GF ;
GRAHAM, RS ;
HUFF, RM .
NATURE, 1990, 343 (6255) :266-269
[8]  
CHIO CL, 1994, MOL PHARMACOL, V45, P51
[9]   NOVEL INDOLODIOXANES WITH ANTIHYPERTENSIVE EFFECTS - POTENT LIGANDS FOR THE 5-HT1A RECEPTOR [J].
ENNIS, MD ;
BAZE, ME ;
SMITH, MW ;
LAWSON, CF ;
MCCALL, RB ;
LAHTI, RA ;
PIERCEY, MF .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (16) :3058-3066
[10]  
ENNIS MD, 1993, CURR OPIN INVEST DRU, V2, P271